Zoetis Inc. (NYSE:ZTS) Shares Sold by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,364 shares of the company’s stock after selling 207 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Zoetis were worth $861,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC lifted its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares in the last quarter. Independence Bank of Kentucky increased its holdings in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Ramirez Asset Management Inc. purchased a new position in Zoetis in the third quarter valued at about $35,000. First Financial Corp IN lifted its stake in shares of Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after purchasing an additional 79 shares in the last quarter. Finally, Bogart Wealth LLC raised its holdings in shares of Zoetis by 188.9% during the 3rd quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after buying an additional 170 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is owned by insiders.

Zoetis Stock Performance

NYSE:ZTS traded down $6.39 during mid-day trading on Wednesday, hitting $162.06. The stock had a trading volume of 761,286 shares, compared to its average volume of 3,152,585. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. The stock has a market capitalization of $73.95 billion, a price-to-earnings ratio of 32.46, a P/E/G ratio of 2.57 and a beta of 0.86. The company has a 50 day simple moving average of $167.64 and a 200-day simple moving average of $178.93.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.31 earnings per share. On average, research analysts expect that Zoetis Inc. will post 5.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ZTS. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Stifel Nicolaus cut their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Finally, The Goldman Sachs Group decreased their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $212.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.